PT  - JOURNAL ARTICLE
AU  - Heli Harvala
AU  - Matthew L Robb
AU  - Nick Watkins
AU  - Samreen Ijaz
AU  - Steven Dicks
AU  - Monika Patel
AU  - Piyada Supasa
AU  - Wanwisa Dejnirattisai
AU  - Chang Liu
AU  - Juthathip Mongkolsapaya
AU  - Abbie Brown
AU  - Daniel Bailey
AU  - Richard Vipond
AU  - Nicholas Grayson
AU  - Nigel Temperton
AU  - Sunetra Gupta
AU  - Rutger J Ploeg
AU  - Jai Bolton
AU  - Alex Fyfe
AU  - Robin Gopal
AU  - Peter Simmonds
AU  - Gavin Screaton
AU  - Craig Thompson
AU  - Tim Brooks
AU  - Maria Zambon
AU  - Gail Miflin
AU  - David J Roberts
TI  - Convalescent plasma therapy for the treatment of patients with COVID-19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels
AID  - 10.1101/2020.05.20.20091694
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.20.20091694
4099  - http://medrxiv.org/content/early/2020/05/26/2020.05.20.20091694.short
4100  - http://medrxiv.org/content/early/2020/05/26/2020.05.20.20091694.full
AB  - Introduction The lack of approved specific therapeutic agents to treat COVID-19 associated with SARS coronavirus 2 (SARS-CoV-2) infection has led to the rapid implementation and/or randomised controlled trials of convalescent plasma therapy (CPT) in many countries including the UK. Effective CPT is likely to require high titres of neutralising antibody levels in convalescent donations. Understanding the relationship between functional neutralising antibodies and antibody levels to specific SARS-CoV-2 proteins in scalable assays will be crucial for the success of large-scale collection and use of convalescent plasma. We assessed whether neutralising antibody titres correlated with reactivity in a range of ELISA assays targeting the spike (S) protein, the main target for human immune response.Methods Blood samples were collected from 52 individuals with a previous laboratory confirmed SARS-CoV-2 infection at least 28 days after symptom resolution. These were assayed for SARS-CoV-2 neutralising antibodies by native virus and lentiviral pseudotype assays, and for antibodies by four different ELISAs measuring antibody binding to different format of viral S proteins. ROC analysis was used to further identify sensitivity and specificity of selected assays to identify samples containing high neutralising antibody levels suitable for clinical use of convalescent plasma.Results All samples contained SARS-CoV-2 antibodies, whereas neutralising antibody titres of greater than 1:20 were detected in 43 samples (83% of those tested) and >1:100 in 22 samples (42%). The best correlations were observed with EUROimmun IgG ELISA S/CO reactivity (Spearman Rho correlation co-efficient 0.88; p<0.001). Based on ROC analysis, EUROimmun would detect 60% of samples with titres of >1:100 with 100% specificity using a reactivity index of 9.1 (13/22).Discussion Robust associations between virus neutralising antibody titres and reactivity in several ELISA-based antibody tests demonstrate their possible utility for scaled-up production of convalescent plasma containing potentially therapeutic levels of anti-SARS-CoV-2 neutralising antibodies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Medical Research Council [grant number MC_PC_19059]. National Institute for Health Research Biomedical Research Centre Funding Scheme (to G.R.S.), the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Science (CIFMS), China (grant number: 2018-I2M-2-002). PK, PS and G.R.S. is supported as a Wellcome Trust Senior Investigator (grant 095541/A/11/Z; WT109965/MA). PK is an NIHR Senior Investigator. NG was supported via grant to Philip Goulder (WTIA Grant WT104748MA) and a grant to John Frater (Medical Research Council MR/L006588/1). CPT was funded by an ERC research grant ‘UNIFLUVAC’ and two MRC CiC grants (Ref: BR00140).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used in the study is available from the corresponding author (Heli.HarvalaSimmonds{at}nhsbt.nhs.uk) on request